[
    "{\"step_by_step_thinking\": \"Amantadine ER is mentioned in several documents. Document [1] mentions that amantadine is typically administered orally once daily or in divided doses depending on the indication. Document [2] states that Amantadine extended release (ER) is currently the only FDA-approved medication for the treatment of LID. Document [3] mentions that in February 2018, OS320-an amantadine extended-release (ER) tablet formulation with once-daily morning administration-was approved for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults. Document [29] also states that in 2017, the U.S. Food and Drug Administration approved the use of amantadine in an extended release formulation for the treatment of dyskinesia, an adverse effect of levodopa in people with Parkinson's disease. These documents clearly indicate that amantadine ER has been approved by the FDA.\", \"answer_choice\": \"A\"}"
]